Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.50 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.50 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.50 |
| ▸ | IKZF2 | Q9UKS7 | 9/20 | 0.49 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32671757 | 1.00 | CRBN (0.53) | CRBNCSNK1A1DDB1GSPT1IKZF3 | |
| SCHEMBL23860842 | 0.90 | IKZF2 (0.54) | CRBNCSNK1A1DDB1GSPT1IKZF3 | |
| SCHEMBL30133423 | 0.87 | CRBN (0.54) | CRBNCSNK1A1DDB1GSPT1IKZF3 | |
| SCHEMBL23860993 | 0.87 | CRBN (0.54) | CRBNCSNK1A1DDB1GSPT1IKZF3 | |
| SCHEMBL25948346 | 0.84 | CRBN (0.54) | CRBNCSNK1A1IKZF2IKZF1 | |
| SCHEMBL23860795 | 0.84 | CRBN (0.61) | CRBNCSNK1A1DDB1GSPT1IKZF3 | |
| SCHEMBL26534442 | 0.84 | CRBN (0.61) | CRBNCSNK1A1DDB1GSPT1IKZF3 | |
| SCHEMBL27328978 | 0.82 | CRBN (0.55) | CRBNCSNK1A1DDB1GSPT1IKZF3 | |
| SCHEMBL27283350 | 0.81 | CRBN (0.57) | CRBNCSNK1A1DDB1GSPT1IKZF3 | |
| SCHEMBL30133232 | 0.81 | CRBN (0.61) | CRBNCSNK1A1DDB1GSPT1IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| EP-4126843-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | Bristol-Myers Squibb Company (US) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021194914-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021194914-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | DDX21, HRAS, RPL17 | CRBN 867/4885CSNK1A1 963/4885DDB1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.